கேட்லின் கருசோ கூர்மையான News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கேட்லின் கருசோ கூர்மையான. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கேட்லின் கருசோ கூர்மையான Today - Breaking & Trending Today

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical. ....

United States , Acta Oncologica , Danielh Ahn , Katelyn Caruso Sharpe , Mark Erlander , Vicki Kelemen , Joyce Allaire , Cardiff Oncology Inc , Inova Schar Cancer Institute , Cancer Center , Prnewswire Cardiff Oncology Inc , Exchange Commission , Lifesci Communications , Kansas University , Norris Comprehensive Cancer Center , Mayo Clinic Cancer Center , Cardiff Oncology , Mayo Clinic Arizona , Line Treatment , Metastatic Colorectal Cancer , Mayo Clinic , Medical Center , Inova Schar Cancer Institute For , Polo Like Kinase , Private Securities Litigation Reform Act , Oncology Contact ,

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC

Share this article
SAN DIEGO, April 10, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced observations from its Expanded Access Program (EAP) of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Cardiff Oncology s EAP has enrolled participants who failed or progressed on multiple lines of standard-of-care treatment and uses the same combination regimen (onvansertib 15 mg/m ....

United States , Katelyn Caruso Sharpe , Mark Erlander , Vicki Kelemen , Joyce Allaire , Manishr Sharma , Exchange Commission , Cardiff Oncology Inc , American Association For Cancer Research , Lifesci Communications , Prnewswire Cardiff Oncology Inc , Access Program , Expanded Access Program , American Association , Cancer Research , Annual Meeting , Cardiff Oncology , Evaluable Patients , Colorectal Cancer , Polo Like Kinase , Private Securities Litigation Reform Act , Oncology Contact , ஒன்றுபட்டது மாநிலங்களில் , கேட்லின் கருசோ கூர்மையான , மகிழ்ச்சி அல்லேர் , பரிமாற்றம் தரகு ,

Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC

Share this article
SAN DIEGO, April 10, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology (MIT), today announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021. ....

Dana Farber Cancer Institute , United States , Massachusetts Institute Of Technology , Davidh Koch , Michaelb Yaffe , David Einstein , Katelyn Caruso Sharpe , Mark Erlander , Vicki Kelemen , Joyce Allaire , Cardiff Oncology Inc , Hospital Cancer Center , Beth Israel Deaconess Medical Center , Prnewswire Cardiff Oncology Inc , Exchange Commission , Genitourinary Oncology Program , American Association For Cancer Research , Lifesci Communications , Precision Cancer Medicine , Massachusetts Institute , American Association , Cancer Research , Annual Meeting , Cardiff Oncology , Biological Engineering , Decipher Biosciences ,

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Katelyn Caruso Sharpe , Mark Erlander , Vicki Kelemen , Joyce Allaire , Manishr Sharma , Exchange Commission , Cardiff Oncology Inc , Lifesci Communications , Access Program , Cardiff Oncology , Expanded Access Program , Evaluable Patients , Colorectal Cancer , Polo Like Kinase , Private Securities Litigation Reform Act , Oncology Contact , கேட்லின் கருசோ கூர்மையான , மகிழ்ச்சி அல்லேர் , பரிமாற்றம் தரகு , கார்டிஃப் புற்றுநோயியல் இன்க் , நுழைவு ப்ரோக்ர்யாம் , கார்டிஃப் புற்றுநோயியல் , விரிவாக்கப்பட்டது நுழைவு ப்ரோக்ர்யாம் , பெருங்குடல் புற்றுநோய் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , புற்றுநோயியல் தொடர்பு ,

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021
News provided by
Share this article
SAN DIEGO, March 10, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Details on the electronic posters and corresponding abstracts are shown below.
Title: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer ....

United States , Dana Farber Cancer Institute , David Einstein , Katelyn Caruso Sharpe , Vicki Kelemen , Joyce Allaire , Clinical Outcomes Research , Cardiff Oncology Inc , Hospital Cancer Center , Beth Israel Deaconess Medical Center , Prnewswire Cardiff Oncology Inc , Cardiff Oncology Expanded Access Program , Clinical Research Excluding Trials , Genitourinary Oncology Program , American Association For Cancer Research , Lifesci Communications , Access Program , American Association , Cancer Research , Annual Meeting , Clinical Research , Excluding Trials , Clinical Outcomes , Cardiff Oncology , Expanded Access Program , Cell Cycle Mechanisms ,